These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 30377939)

  • 1. Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC.
    Shamni O; Grievink H; Itamar B; Mishani E; Abourbeh G
    Mol Imaging Biol; 2019 Aug; 21(4):696-704. PubMed ID: 30377939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Traxl A; Beikbaghban T; Wanek T; Kryeziu K; Pirker C; Mairinger S; Stanek J; Filip T; Sauberer M; Kuntner C; Berger W; Langer O
    Nucl Med Biol; 2017 Sep; 52():7-15. PubMed ID: 28575795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of 6-O-[
    Shi D; Dong Y; Zhou W; Bai L; Huang J; Han Y; Sun P; Huang Y; Huang Y; Chen L; Cao M; Wu H; Huang S
    Bioorg Med Chem Lett; 2023 Apr; 85():129217. PubMed ID: 36889652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
    Ullrich RT; Zander T; Neumaier B; Koker M; Shimamura T; Waerzeggers Y; Borgman CL; Tawadros S; Li H; Sos ML; Backes H; Shapiro GI; Wolf J; Jacobs AH; Thomas RK; Winkeler A
    PLoS One; 2008; 3(12):e3908. PubMed ID: 19079597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD147-mediated glucose metabolic regulation contributes to the predictive role of
    Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
    Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
    Furugaki K; Iwai T; Shirane M; Kondoh K; Moriya Y; Mori K
    Oncol Rep; 2010 Nov; 24(5):1141-6. PubMed ID: 20878103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
    Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
    Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
    Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
    Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
    Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
    Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
    Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
    Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
    J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
    Bahce I; Smit EF; Lubberink M; van der Veldt AA; Yaqub M; Windhorst AD; Schuit RC; Thunnissen E; Heideman DA; Postmus PE; Lammertsma AA; Hendrikse NH
    Clin Cancer Res; 2013 Jan; 19(1):183-93. PubMed ID: 23136193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
    Abourbeh G; Itamar B; Salnikov O; Beltsov S; Mishani E
    EJNMMI Res; 2015; 5():4. PubMed ID: 25853010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.
    Memon AA; Weber B; Winterdahl M; Jakobsen S; Meldgaard P; Madsen HH; Keiding S; Nexo E; Sorensen BS
    Br J Cancer; 2011 Dec; 105(12):1850-5. PubMed ID: 22095231
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jain A; Kameswaran M; Pandey U; Prabhash K; Sarma HD; Dash A
    Bioorg Med Chem Lett; 2017 Oct; 27(19):4552-4557. PubMed ID: 28893469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
    Memon AA; Jakobsen S; Dagnaes-Hansen F; Sorensen BS; Keiding S; Nexo E
    Cancer Res; 2009 Feb; 69(3):873-8. PubMed ID: 19155297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.